Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults With Severe Uncontrolled Asthma

NCT03927157 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03927157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03927157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults With Severe Uncontrolled Asthma
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 14, 2019
Completion date
August 13, 2024
Enrollment
405 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

asthma